IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB

NCT03734783 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2019-11-18

No results posted yet for this study

Summary

The investigators observed the level of IL-35 secreting B regulatory (IL-35+Bregs) cells in peripheral blood cells in patients with chronic hepatitis B, and analysed the relationship between the IL-35+Bregs level and disease stage, and Th1 and Th2 cells level.

Conditions

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Eligibility

Min Age
17 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2019-11-15
Completion
2019-11-15

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03734783 on ClinicalTrials.gov